Flt3-ITD mutations can generate leukaemia specific neoepitopes: Potential role for immunotherapeutic approaches

Leukemia and Lymphoma

Volumn 47, Issue 2, 2006, Pages 307-312

  Scholl, Sebastian ^a   Salzmann, S ^a   Kaufmann, A ^a   Hoffken K ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

AML; Flt3 ITD; Immunotherapy; Mimotope; Neoepitope

Indexed keywords

EPITOPE; FLT3 LIGAND; HLA A1 ANTIGEN; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; HLA B27 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO ACID SEQUENCE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; GENE FUSION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TUMOR CELL LINE;

ACUTE DISEASE; CELL LINE, TUMOR; EPITOPES; FMS-LIKE TYROSINE KINASE 3; GENES, MHC CLASS I; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID; MUTATION; PEPTIDE FRAGMENTS;

EID: 30644477496     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500301306     Document Type: Article

References (17)

1. Nakao, M and Yokota, S and Iwai, T and Kaneko, H and Horiike, S and Kashima, K and (1996) Internal tandem duplication of the flt3 gene found in acute myeloid leukemia Leukemia, 10, pp. 1911 - 1918.
2. Kiyoi, H and Naoe, T and Yokota, S and Nakao, M and Minami, S and Kuriyama, K and (1997) Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho) Leukemia, 11, pp. 1447 - 1452.
3. Kottaridis, P and Gale, R and Frew, M and Harrison, G and Langabeer, S and Belton, A and (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials Blood, 98, pp. 1752 - 1759.
4. Thiede, C and Steudel, C and Mohr, B and Schaich, M and Schakel, U and Platzbecker, U and (2002) Analysis of Flt3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis Blood, 99, pp. 4326 - 4335.
5. Abu-Duhier, F and Goodeve, A and Wilson, G and Gari, M and Peake, I and Rees, D and (2000) FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group Br J Haematol, 111, pp. 190 - 195.
6. Kiyoi, H and Ohno, R and Ueda, R and Saito, H and Naoe, T. (2002) Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain Oncogene, 21, pp. 2555 - 2563.
7. Clark, R and Dodi, I and Hill, S and Lill, J and Aubert, G and Macintyre, G and (2001) Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the Bcr-Abl b3a2 fusion protein Blood, 98, pp. 2887 - 2893.
8. Nieda, M and Nicol, A and Kikuchi, A and Kashiwase, K and Taylor, K and Suzuki, K and (1998) Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia Blood, 91, pp. 977 - 983.
9. Mannering, S and McKenzie, J and Fearnley, D and Hart, D. (1997) HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates Blood, 90, pp. 290 - 297.
10. Pinilla-Ibarz, J and Cathcart, K and Korontsvit, T and Soignet, S and Bocchia, M and Caggiano, J and (2000) Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogen breakpoint fusion protein generates specific immune responses Blood, 95, pp. 1781 - 1787.
11. He, L and Feng, H and Raymond, A and Kreeger, M and Zeng, Y and Graner, M and (2001) Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice Cancer Immunol Immunother, 50, pp. 31 - 40.
12. Linnemann, T and Tumenjargal, S and Gellrich, S and Wiesmuller, K and Kaltoft, K and Sterry, W and (2001) Mimotopes for tumor-specific T lymphocytes in human cancer determined with combinatorial peptide libraries Eur J Immunol, 31, pp. 156 - 165.
13. Parker, K and Shields, M and DiBrino, M and Brooks, A and Coligan, J. (1995) Peptide binding to MHC class I molecules: Implications for antigenic peptide prediction Immunol Res, 14, pp. 34 - 57.
14. Parker, K and Bednarek, M and Coligan, J. (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains J Immunol, 152, pp. 163 - 175.
15. Vollmer, M and Li, L and Schmitt, A and Greiner, J and Reinhardt, P and Ringhoffer, M and (2003) Expression of human leucocyte antigens and co-stimulatory molecules on blasts of patients with acute myeloid leukaemia Br J Haematol, 120, pp. 1000 - 1008.
16. Brouwer, R and van der Heiden, P and Schreuder, G and Mulder, A and Datema, G and Anholts, J and (2002) Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon Hum Immunol, 63, pp. 200 - 210.
17. Robin, M and Schlageter, M and Chomienne, C and Padua, R. (2005) Targeted immunotherapy in acute myeloblastic leukemia: From animals to humans Cancer Immunol Immunother, 54, pp. 933 - 943.